Beneficial effects of denosumab on muscle performance in patients with low BMD: a retrospective, propensity score-matched study.
Chair rising test
DXA
Denosumab
Grip force
Osteosarcopenia
Journal
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
ISSN: 1433-2965
Titre abrégé: Osteoporos Int
Pays: England
ID NLM: 9100105
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
24
02
2022
accepted:
13
06
2022
pubmed:
26
6
2022
medline:
12
10
2022
entrez:
25
6
2022
Statut:
ppublish
Résumé
This study examined the effects of denosumab compared to bisphosphonates and vitamin D alone on muscle performance in patients with low BMD. While grip force improved in both the denosumab and bisphosphonate group, a superior increase in chair rising test force was observed in the denosumab group. The aim of this study was to investigate the effect of the anti-resorptive agent denosumab (Dmab) on upper and lower limb muscle performance compared to bisphosphonate (BP) treatment and vitamin D supplementation alone (i.e., basic therapy) in patients with low BMD. This retrospective, propensity score-matched (sex, age, BMI, follow-up time) cohort study included 150 osteopenic or osteoporotic patients receiving basic (n = 60), BP (n = 30) or Dmab (n = 60) therapy. All patients underwent a musculoskeletal assessment at baseline and follow-up, including DXA, laboratory bone metabolism parameters, grip force, and chair rising test mechanography. Mean annual percentage changes were calculated and compared between study groups. After a mean follow-up period of 17.6 ± 9.0 months, a significantly higher increase in grip force in both the Dmab (p < 0.001) and BP group (p = 0.001) compared to the vitamin D group was observed (vitamin D = - 6.1 ± 10.2%; BP = + 0.8 ± 8.2%; Dmab = + 5.1 ± 25.5%). The Dmab group showed a significantly higher increase in chair rising test force compared to the BP group (vitamin D = + 5.8 ± 12.7%; BP = + 0.9 ± 8.6%; Dmab = + 8.2 ± 14.4%; Dmab vs. BP p = 0.03). Neither the changes in BMD nor in bone metabolic parameters were associated with changes in muscle performance. Dmab resulted in increased muscle strength in the upper and lower limbs, indicating systemic rather than site-specific effects as compared to BP. Based on these findings, Dmab might be favored over other osteoporosis treatments in patients with low BMD and poor muscle strength.
Identifiants
pubmed: 35751664
doi: 10.1007/s00198-022-06470-3
pii: 10.1007/s00198-022-06470-3
pmc: PMC9546982
doi:
Substances chimiques
Bone Density Conservation Agents
0
Diphosphonates
0
Vitamin D
1406-16-2
Denosumab
4EQZ6YO2HI
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2177-2184Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2022. The Author(s).
Références
Front Med (Lausanne). 2021 May 20;8:612506
pubmed: 34095158
J Clin Endocrinol Metab. 2014 Nov;99(11):4336-45
pubmed: 25033068
JBMR Plus. 2017 Oct;1(2):86-100
pubmed: 29104955
J Gerontol A Biol Sci Med Sci. 2022 Oct 6;77(10):2085-2092
pubmed: 35018430
Hum Mol Genet. 2019 Sep 15;28(18):3101-3112
pubmed: 31179501
Internist (Berl). 2017 Oct;58(10):1029-1036
pubmed: 28835974
Front Cell Dev Biol. 2020 Dec 10;8:585644
pubmed: 33363144
J Clin Invest. 2005 Dec;115(12):3318-25
pubmed: 16322775
Clin Rheumatol. 2021 Oct;40(10):4225-4232
pubmed: 34008069
Arch Osteoporos. 2018 Jul 2;13(1):71
pubmed: 29968169
Int J Surg. 2014 Dec;12(12):1495-9
pubmed: 25046131
Rheumatology (Oxford). 2021 Feb 1;60(2):529-537
pubmed: 33276373
PLoS One. 2019 Apr 30;14(4):e0215826
pubmed: 31039170
Osteoporos Int. 2021 Nov;32(11):2173-2183
pubmed: 33877382
J Clin Invest. 2019 May 23;129(8):3214-3223
pubmed: 31120440
J Bone Miner Res. 2020 Jun;35(6):1014-1021
pubmed: 31999376
J Clin Densitom. 2009 Oct-Dec;12(4):413-6
pubmed: 19733110
Ann Rheum Dis. 2014 Sep;73(9):1635-45
pubmed: 24692584
J Am Geriatr Soc. 2019 Dec;67(12):2660-2661
pubmed: 31483858
Calcif Tissue Int. 2015 Mar;96(3):243-55
pubmed: 25633430
Bone. 2011 Apr 1;48(4):952-7
pubmed: 21195216
Bone. 2022 Jan;154:116245
pubmed: 34718221
Proc Natl Acad Sci U S A. 2015 Sep 29;112(39):12157-62
pubmed: 26374841
Int J Endocrinol. 2020 Nov 06;2020:1809150
pubmed: 33204260
J Cachexia Sarcopenia Muscle. 2020 Jun;11(3):609-618
pubmed: 32202056
Arch Orthop Trauma Surg. 2012 Dec;132(12):1781-8
pubmed: 23053191
Nat Med. 2015 Sep;21(9):1085-90
pubmed: 26236992
Ann Rheum Dis. 2014 Aug;73(8):1462-9
pubmed: 24590181
Am J Physiol Cell Physiol. 2016 Apr 15;310(8):C663-72
pubmed: 26825123
J Bone Miner Res. 2022 Mar;37(3):420-427
pubmed: 34954857
Arch Public Health. 2014 Dec 18;72(1):45
pubmed: 25810912
Mol Metab. 2016 Jul 16;5(10):1042-1047
pubmed: 27689017
Nat Rev Drug Discov. 2012 May;11(5):401-19
pubmed: 22543469